Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

Published:2015-03-14 Issue:14 Volume:6 Page:12035-12047
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Braig Friederike¹,März Manuela¹,Schieferdecker Aneta¹,Schulte Alexander²,Voigt Mareike¹,Stein Alexander¹,Grob Tobias³,Alawi Malik⁴,Indenbirken Daniela⁵,Kriegs Malte⁶,Engel Erik⁷,Vanhoefer Udo⁸,Grundhoff Adam⁵,Loges Sonja¹⁹,Riecken Kristoffer¹⁰,Fehse Boris¹⁰,Bokemeyer Carsten¹,Binder Mascha¹

Affiliation:

1. Department of Oncology and Hematology, BMT with section Pneumology, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Department of Neurosurgery, Laboratory for Brain Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

3. Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

4. Bioinformatics Service Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

5. Heinrich-Pette-Institute, Leibniz-Institute for Experimental Virology (HPI), Hamburg, Germany

6. Radiation Biology and Radio-Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

7. Hämatologisch-onkologische Praxis Altona (HOPA), Hamburg, Germany

8. Marienkrankenhaus, Zentrum für Innere Medizin, Hamburg, Germany

9. Institute for Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

10. Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies;Advanced Science;2024-01-29

2. Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer;Biomedicines;2023-06-01

3. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling;Frontiers in Oncology;2022-09-14

4. Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance;Nature Communications;2022-07-30

5. PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition;Frontiers in Oncology;2022-07-22